Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
19,186,334
-
Share change
-
-305,661
-
Total reported value
-
$28,011,450
-
Put/Call ratio
-
147%
-
Price per share
-
$1.46
-
Number of holders
-
52
-
Value change
-
-$1,230,963
-
Number of buys
-
25
-
Number of sells
-
21
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2023
As of 30 Sep 2023 Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) had 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 19,186,334 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, SAMLYN CAPITAL, LLC, BVF INC/IL, VANGUARD GROUP INC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, TOWERVIEW LLC, and TWO SIGMA INVESTMENTS, LP.
This table shows 52 institutional shareholders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.